Regenacy Pharma
Boston
Massachusetts
United States
About Regenacy Pharma
Regenacy Pharmaceuticals, LLC focuses on the development of novel drug candidates that selectively regenerate intracellular transport and upregulate gene expression to modify the course of disease.LEADERSHIP:
CEO: Walter C. Ogier
12 articles about Regenacy Pharma
-
Regenacy Pharmaceuticals Appoints David Michelson, M.D., as Chief Medical Officer
4/23/2020
Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, announced the appointment of David Michelson, M.D., as Chief Medical Officer.
-
Regenacy Pharmaceuticals Raises $30 Million in Series A Financing
3/25/2020
Financing co-led by Cobro Ventures and Taiwania Capital Management Corporation; Michael Huang, Managing Partner at Taiwania joins the Regenacy Board of Directors- WALTHAM, Mass.--( BUSINESS WIRE )-- Regenacy Pharmaceuticals , a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the closing of a $30 million Series A financing. The financing was co-led by Cobro
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Regenacy Pharmaceuticals Announces Collaboration with the Charcot-Marie-Tooth Association (CMTA) to Advance Ricolinostat for the Treatment of Hereditary Neuropathy
8/2/2018
Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced a collaboration with the Charcot-Marie-Tooth Association (CMTA), a registered non-profit organization serving the hereditary neuropathy patient community.
-
Regenacy Pharmaceuticals Appoints Dr. William W. Chin to Board of Directors and Scientific Advisory Board
4/17/2018
Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, announced today the appointment of William (Bill) W. Chin, M.D., to its Board of Directors and Scientific Advisory Board.
-
Regenacy Pharmaceuticals to Present a Corporate Update at the 10th Annual Biotech Showcase
12/19/2017
Regenacy announced today that Simon S. Jones, Ph.D., President and Chief Executive Officer of Regenacy, is scheduled to present a corporate update at the 10th Annual Biotech Showcase.
-
Regenacy Pharma Presents Data Demonstrating That HDAC1,2 Inhibition Improved Cognitive Function In Mouse Models Of Alzheimer's Disease At The Alzheimer’s Association International Conference
7/20/2017
-
Regenacy Pharma Presents Data Demonstrating That HDAC1,2 Inhibition Improved Cognitive Function In Mouse Models Of Alzheimer's Disease At The Alzheimer’s Association International Conference
7/19/2017
-
Regenacy Pharma Appoints Simon S. Jones As President And Chief Executive Officer
6/27/2017
-
Regenacy Pharma Demonstrates Reversal Of Chemotherapy-Induced Peripheral Neuropathy With HDAC6 Inhibitor Ricolinostat In Preclinical Model
3/8/2017
-
Regenacy Pharma Release: Pharma's HDAC1,2 Inhibitors Demonstrate Single-Agent And Synergistic Activity With Azacitidine (Vidaza) In Preclinical Models Of Acute Myeloid Leukemia
1/11/2017
-
Boston's Acetylon Gets Taken Out By Celgene, Will Spin Out Startup Regenacy Pharma
12/6/2016